Otsuka's OPC-167832 Trial for Drug-Susceptible TB Shows Promise Against Standard Regimen
A trial is underway to evaluate the safety and efficacy of OPC-167832 in combination with delamanid and bedaquiline for drug-susceptible TB.
Company
Pharmaceutical intelligence for Otsuka Pharmaceutical Development & Commercialization, Inc. with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.